[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Copenhagen Respiratory Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100584658","phase-4-comparing-hydrocortisone-and-prednisolone-for-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-aecopd-100584658",false,"NCT06892210","Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","Inclusion Criteria:\n\n* Age ≥40 years\n* Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44\n\nExclusion Criteria:\n\n* All diagnoses that would merit treatment with a specific corticosteroid\n* Pregnant or breastfeeding women\n* Active tuberculosis or invasive fungal infection","ALL","40 Years",{"count":18,"type":19},2000,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days.\n\nParticipants will randomized to receive treatment with either hydrocortisone or prednisolone.",[25],"Chronic Obstructive Pulmonary Disease (COPD)","RECRUITING","2026-03-16",{"date":29,"type":30},"2026-03-18","ACTUAL",{"date":32,"type":30},"2026-03-10",{"date":34,"type":19},"2030-11-01",{"name":36,"class":37},"Copenhagen Respiratory Research","NETWORK",14,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":54,"leadSponsor":55,"locationsCount":38},"100584657","phase-4-comparing-hydrocortisone-and-prednisolone-for-community-acquired-pneumonia-cap-100584657","NCT06892197","Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP.\n\nExclusion Criteria:\n\n* Admitted \\>24 h\n* Pregnant or breastfeeding women\n* Active tuberculosis or fungal infection\n* Pneumonia caused by influenza\n* Intolerance to either study drug","18 Years",{"count":47,"type":19},1600,[22],"The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days.\n\nParticipants will be randomized to receive treatment with either hydrocortisone or prednisolone.",[51],"Community Acquired Pneumonia (CAP)",{"date":29,"type":30},{"date":32,"type":30},{"date":34,"type":19},{"name":36,"class":37},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":20,"phases":66,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100582141","phase-2-local-antibiotic-delivery-for-community-acquired-pneumonia-100582141","NCT06859450","Local Antibiotic Delivery for Community Acquired Pneumonia","Local Antibiotic Delivery for Community Acquired Pneumonia - Pilot Study (LANDCAP1)","LANDCAP-1","Inclusion Criteria:\n\n1. Hospital admission within 24 hours.\n2. Radiologically new-onset chest infiltrate that is consistent with pneumonia and symptoms or signs also consistent with pneumonia, such as fever, cough, sputum, dyspnoea and\u002For chest pain\n3. CURB-65 score 3-5\n4. C-reactive protein \\>50 OR central body temperature \\>38.0 °C (1-2 of these fulfilled)\n5. Age ≥ 18 years\n6. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Septic shock according to the sepsis III criteria:41 sequential organ failure assessment (SOFA) score ≥2) and suspected infection (according to attending physician) and persisting hypotension requiring vasopressors to maintain MAP≥65 mmHg and serum lactate level\\>2 mmol\u002FL (18 mg\u002FdL) despite adequate volume resuscitation (30 mL\u002Fkg crystalloid within 3 hours).\n2. Oxygen requirement ≥5 L\u002Fmin to maintain acceptable saturation assessed by the treating physician.\n3. Respiratory rate \\>24\u002Fmin with relevant oxygen therapy\n4. Positive COVID or influenza test (PCR or antigen test)\n5. Known allergy to levofloxacin or other fluoroquinolones or a serious adverse reaction when previously treated with a fluoroquinolone, including tendinitis or tendon-rupture related to fluoroquinolone treatment\n6. Symptoms of neuropathy (peripheral paraesthesia, hypoesthesia, or hyperalgesia)\n7. Known allergy to β-lactam antibiotics or to macrolide antibiotics.\n8. Medical history of myasthenia gravis\n9. Reduced kidney function (eGFR \\\u003C 20)\n10. Expected transfer to ICU or death within 48 hours or a do not resuscitate ordination at time of recruitment.\n11. Suspected aspiration pneumonia, pulmonary abscess, or pleural empyema \u002F complicated parapneumonic effusion.\n12. Clinically significant cardiac conduction disorders\u002Farrhythmias or prolonged QTc interval (QTc (f) \\> 480ms).\n13. Pregnancy (a negative pregnancy test is required prior to inclusion of all pre-menopausal women)",{"count":65,"type":19},36,[67,68],"PHASE2","PHASE3","A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.",[51],[72,73,74,75,76,77,78,79],"Community Acquired Pneumonia","Inhaled levofloxacin","Inhaled antibiotics","feasibility","Chronic obstructive pulmonary disease","asthma","pulmonary healthy","pilot study","NOT_YET_RECRUITING","2025-03-05",{"date":83,"type":30},"2025-03-10",{"date":85,"type":19},"2025-03-04",{"date":87,"type":19},"2028-09-01",{"name":36,"class":37},""]